Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lees, A. W.
Right arrow Articles by Hoy, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lees, A. W.
Right arrow Articles by Hoy, W.

Chest, Vol 75, 51-53, Copyright © 1979 by American College of Chest Physicians

ARTICLES

Management of pleural effusions in breast cancer

AW Lees and W Hoy

Ninety-seven patients with breast cancer developed pleural effusions between January, 1971 and December, 1976. A retrospective analysis of 170 treatment procedures showed that 75 involved thoracocentesis alone, 23 involved thoracocentesis plus therapy with an alkylating agent, 22 involved drainage via a chest tube plus instillation of an alkylating agent, and 50 involved drainage via a chest tube plus instillation of tetracycline. The results are presented as censored survival curves. When management by chest tube plus instillation of an alkylating agent or tetracycline was compared with management by thoracocentesis plus therapy with an alkylating agent, analysis at six months after treatment showed that 42 percent (30/72) of the procedures left patients free of effusion using the former method, compared with 22 percent (5/23) of the procedures using the latter method. This is not quite significant at the 5 percent level using a summary chi2 procedure. The reasons for preferring tetracycline as a sclerosing agent are discussed.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
V.B. Antony, R. Loddenkemper, P. Astoul, C. Boutin, P. Goldstraw, J. Hott, F. Rodriguez Panadero, and S.A. Sahn
Management of malignant pleural effusions
Eur. Respir. J., August 1, 2001; 18(2): 402 - 419.
[Full Text] [PDF]

Home page
 ChestHome page
A. Fujita, H. Takabatake, S. Tagaki, and K. Sekine
Combination Chemotherapy in Patients With Malignant Pleural Effusions From Non-small Cell Lung Cancer : Cisplatin, Ifosfamide, and Irinotecan With Recombinant Human Granulocyte Colony-Stimulating Factor Support
Chest, February 1, 2001; 119(2): 340 - 343.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Management of Malignant Pleural Effusions
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1987 - 2001.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by the American College of Chest Physicians.